Posts

ISB researchers have uncovered a stealth survival strategy that melanoma cells use to evade targeted therapy, offering a promising new approach to improving treatment outcomes.

Scientists at the Institute for Systems Biology (ISB) reveal how T cells “decide” their fate in fighting infections like COVID-19, paving the way for improved treatments for infections, cancer, and autoimmune diseases.

ISB hosted a virtual event to share updates on the ongoing RECOVER study, a national NIH-funded initiative to understand and address Long COVID. 

Reflecting on the past year, ISB has a lot to celebrate: groundbreaking research published in leading scientific journals, well-earned promotions, widespread media coverage, and more. Enjoy our year-in-review roundup highlighting some of the important, interesting, and impactful highlights of 2024.

Infection, autoimmunity and cancer account for 40 percent of deaths worldwide. In a Cell Reports paper, ISB researchers detail how the human immune system works in common ways across diseases – findings that offer promising avenues for exploring multi-disease therapeutic strategies.

In a breakthrough discovery that changes how we understand T cells and with implications of how we can better engineer custom immune responses to fight disease, Institute for Systems Biology researchers showed that the different disease-fighting functions of different T cells are determined by the genetically encoded T-cell receptor sequence that are unique to those cells.